Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Cambrex Corporation    CBM

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
09/13/2017 09/14/2017 09/15/2017 09/18/2017 09/19/2017 Date
51.1(c) 52.7(c) 53.6(c) 54(c) 53.7(c) Last
408 935 521 107 414 177 494 787 208 175 Volume
+0.10% +3.13% +1.71% +0.75% -0.56% Change
More quotes
Financials ($)
Sales 2017 536 M
EBIT 2017 141 M
Net income 2017 99,0 M
Debt 2017 -
Yield 2017 -
Sales 2018 574 M
EBIT 2018 147 M
Net income 2018 100 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 17,97
P/E ratio 2018 18,16
Capi. / Sales2017 3,30x
Capi. / Sales2018 3,08x
Capitalization 1 767 M
More Financials
Company
Cambrex Corp. engages in the provision of products, services, and technologies to accelerate and improve the development and commercialization of new and generic therapeutics.It supplies to innovator and generic pharmaceutical companies.Its products include generic and branded APIs, controlled... 
Sector
Pharmaceuticals
Calendar
11/03Earnings Release
More about the company
Surperformance© ratings of Cambrex Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on CAMBREX CORPORATION
09/18 Cambrex to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
09/05 CAMBREX : expands North Carolina facility
08/31 CAMBREX : Invests in New Analytical Development and Method Validation Laboratory..
08/30 Cambrex to Present at Upcoming Investor Conferences in September
08/30 Cambrex Invests in New Analytical Development and Method Validation Laborator..
08/26 BASF : API(Active Pharmaceutical Ingredient) Intermediate Market 2017- Hipharma ..
08/17 CAMBREX : Surpasses ChemStewards® Requirements and Qualifies for SOCMA's "Excell..
08/10 CAMBREX : invests $24m in API manufacturing at Iowa facility
08/08 Cambrex Invests $24 Million in New Highly Potent API Manufacturing Capacity a..
08/07 CAMBREX : Reports Second Quarter 2017 Financial Results
More news
Sector news : Pharmaceuticals - NEC
09/19DJStates Push Ahead With Investigation Into Opioid Painkillers
09/19 BAYER : EU agrees to extend deadline for decision on Bayer, Monsanto deal
09/19 BAYER : dismisses antitrust concerns about digital farming
09/19 GLAXOSMITHKLINE : Former GSK CEO and ex-R&D boss move to biotech venture firms
09/19DJBAYER : Applies to Extend EC's Monsanto Deal Review to Early 2018
More sector news : Pharmaceuticals - NEC
Latest Tweets
09/19Cambrex Corporation $CBM Position Trimmed by Prudential Financial Inc.  
09/19Cambrex to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference.. 
09/18Cambrex to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference.. 
09/18$CBM Cambrex to Present at the 2017 Cantor Fitzgerald Global Healthcare Confe.. 
09/18Cambrex to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference.. 
More tweets
Qtime:25
News from SeekingAlpha
09/08 Cambrex Corporation (CBM) Presents At Baird's 2017 Global Healthcare Conferen..
09/06 Cambrex Corporation (CBM) Presents At 2017 Wells Fargo Healthcare Conference ..
08/05 Cambrex's (CBM) CEO Steve Klosk on Q2 2017 Results - Earnings Call Transcript
08/04 Cambrex reports Q2 revenues up 14%; non-GAAP EPS up 12%; revises guidance
08/04 Cambrex EPS in-line, misses on revenue
Chart CAMBREX CORPORATION
Duration : Period :
Cambrex Corporation Technical Analysis Chart | CBM | US1320111073 | 4-Traders
Technical analysis trends CAMBREX CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 66,3 $
Spread / Average Target 23%
EPS Revisions
Managers
NameTitle
Steven M. Klosk President, Chief Executive Officer & Director
Shlomo Yanai Non-Executive Chairman
Shawn P. Cavanagh Chief Operating Officer & Executive Vice President
Tom Vadaketh Chief Financial Officer & Vice President
Peter G. Tombros Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CAMBREX CORPORATION0.09%1 767
JOHNSON & JOHNSON16.70%363 360
NOVARTIS11.20%223 865
ROCHE HOLDING LTD.4.56%219 130
PFIZER9.45%211 705
MERCK AND COMPANY12.38%179 978